article thumbnail

FogPharma’s $178M Funding Leads Way as 7 Biotechs Raise Cash for Cancer Drugs

MedCity News

The biotech’s Series D financing round lays the groundwork to bring its lead program into the clinic in mid-2023, as well as support development of the rest of its pipeline of peptide drugs. FogPharma is preclinical, but not for long.

Leads 299
article thumbnail

Health Tech for Aging Population Punctuates HLTH 2023 [Sponsored]

MedCity News

Health tech to support care for seniors and track the progression of conditions such as Parkinson’s disease and heart failure were on display at HLTH 2023. The National Institute on Aging also added a startup boot camp leading up to HLTH.

Leads 306
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Novartis CEO’s 2023 pay rises 21% as Roche's helmsman nets $11M in his first year

Fierce Pharma

After leading Novartis and Roche through pivotal years in 2023, the CEOs of the Swiss drug giants each netted multimillion-dollar compensation packages. After leading Swiss drug giants Novartis and Roche through pivotal years, their CEOs have each netted multimillion-dollar compensation packages for 2023.

Leads 277
article thumbnail

Novo Nordisk follows Eli Lilly's lead, slashing insulin prices in the US

Fierce Pharma

Novo Nordisk follows Eli Lilly's lead, slashing insulin prices in the US kdunleavy Tue, 03/14/2023 - 10:56

Leads 253
article thumbnail

With Dupixent leading the way, Sanofi’s taking on the 'big players' in respiratory diseases: exec

Fierce Pharma

With Dupixent leading the way, Sanofi’s taking on the 'big players' in respiratory diseases: exec kdunleavy Mon, 05/22/2023 - 07:33

Leads 218
article thumbnail

Novo Nordisk, Eli Lilly lead industrywide sales surge in Q4

Fierce Pharma

In a year that started with more than two-thirds of biopharma companies posting | While Novo Nordisk and Eli Lilly continued to be the biopharma industry growth leaders in the fourth quarter of 2023, many other drugmakers also delivered big gains, including Daiichi Sankyo, Amgen, Teva, GSK and Novartis.

Leads 251
article thumbnail

Novo Nordisk, Eli Lilly's obesity drugs will lead in new drug sales in 2024: Evaluate

Fierce Pharma

Booming demand for blood sugar-modulating diabetes and obesity drugs became the top trend in the biopharma industry in 2023, with two companies—Novo Nordisk and Eli Lilly—overwhelming the market wi | Booming demand for blood sugar-modulating diabetes and obesity drugs became the top trend in the biopharma industry in 2023, with two companies—Novo Nordisk (..)

Sales 259